A

C

AVOLIO , Carlo

Last name: AVOLIO

First name: Carlo

2022 (v1)

Publication

Metadata-only

Is It Time for Ocrelizumab Extended Interval Dosing in Relapsing Remitting MS? Evidence from An Italian Multicenter Experience During the COVID-19 Pandemic

Zanghì, Aurora Avolio, Carlo Signoriello, Elisabetta

In the COVID-19 pandemic era, safety concerns have been raised regarding the risk of severe infection following administration of ocrelizumab (OCR), a B-cell-depleting therapy. We enrolled all relapsing remitting multiple sclerosis (RRMS) patients who received maintenance doses of OCR from January 2020 to June 2021. Data were extracted in...

Uploaded on: February 14, 2024
2022 (v1)

Publication

Metadata-only

Disease-Modifying Treatments and Time to Loss of Ambulatory Function in Patients With Primary Progressive Multiple Sclerosis

Portaccio, Emilio Fonderico, Mattia Iaffaldano, Pietro

IMPORTANCE Except for ocrelizumab, treatment options in primary progressive multiple sclerosis (PPMS) are lacking.OBJECTIVE To investigate the effectiveness of DMTs on the risk of becoming wheelchair dependent in a real-world population of patients with PPMS.DESIGN, SETTING, AND PARTICIPANTS This was a multicenter, observational, retrospective,...

Uploaded on: February 14, 2024